Lunai Bioworks (LNAI)
Market Price (6/23/2026): $4.0 | Market Cap: $12.5 MilSector: Health Care | Industry: Biotechnology
Lunai Bioworks (LNAI)
Market Price (6/23/2026): $4.0Market Cap: $12.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, mRNA Technology, Show more. | Weak multi-year price returns2Y Excs Rtn is -106%, 3Y Excs Rtn is -97% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -47019% Expensive valuation multiplesP/SPrice/Sales ratio is 619x Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 6575% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -25109%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -25109% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -994% High stock price volatilityVol 12M is 938% Key risksLNAI key risks include [1] severe financial distress and a subsidiary's bankruptcy that threaten its viability, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, mRNA Technology, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -106%, 3Y Excs Rtn is -97% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.8 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -47019% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 619x |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 6575% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -25109%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -25109% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -994% |
| High stock price volatilityVol 12M is 938% |
| Key risksLNAI key risks include [1] severe financial distress and a subsidiary's bankruptcy that threaten its viability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 6/22/2026
Lunai Bioworks (LNAI) stock has gained about 40% since 2/28/2026 because of the following key factors:
1. Regained Nasdaq Compliance Following Reverse Stock Split and Addressed Allegations of Naked Short Selling.
Lunai Bioworks' stock experienced significant upward movement after regaining compliance with Nasdaq's minimum bid price requirement. The company announced a 1-for-8 reverse stock split on May 20, 2026, to address its listing requirements. Subsequently, on June 11, 2026 (disclosed June 17, 2026), Nasdaq confirmed Lunai Bioworks had satisfied the $1.00 minimum bid price rule, leading to an 80.88% surge in share price to $5.15 in after-hours trading. Concurrently, the company pursued legal action against unidentified parties for alleged "naked" short-selling and manipulative trading, citing anomalous failures-to-deliver 29.6 million shares (81.6% of outstanding shares) and peak trading volumes of 554 million shares on March 17, 2026, which was 15.3 times its outstanding shares. A federal judge ordered expedited discovery in May fiscal Q4 2026 to identify these defendants.
2. Expansion of AI-Powered Drug Discovery through Strategic Acquisitions and Partnerships.
Lunai Bioworks strengthened its AI-powered drug discovery pipeline through key strategic moves during this period. In March fiscal Q3 2026, the company completed a $20 million preferred issuance to acquire a Blood-Brain Barrier (BBB) Delivery Platform, intended for CNS Alzheimer's therapies and other neurotherapeutic applications. Furthermore, in April fiscal Q4 2026, Lunai Bioworks' subsidiary, BioSymetrics, signed a Letter of Intent with Geneial, Inc. to collaborate on building rare disease patient cohorts for pharmaceutical partnerships, particularly focusing on rare neurological disorders. This was followed by a foundation-funded collaboration with BrainStorm Therapeutics in May fiscal Q4 2026, targeting AI discovery for Parkinson's and rare epilepsy.
Show more
Lunai Bioworks (LNAI) stock has gained about 40% since 2/28/2026 because of the following key factors:
1. Regained Nasdaq Compliance Following Reverse Stock Split and Addressed Allegations of Naked Short Selling.
Lunai Bioworks' stock experienced significant upward movement after regaining compliance with Nasdaq's minimum bid price requirement. The company announced a 1-for-8 reverse stock split on May 20, 2026, to address its listing requirements. Subsequently, on June 11, 2026 (disclosed June 17, 2026), Nasdaq confirmed Lunai Bioworks had satisfied the $1.00 minimum bid price rule, leading to an 80.88% surge in share price to $5.15 in after-hours trading. Concurrently, the company pursued legal action against unidentified parties for alleged "naked" short-selling and manipulative trading, citing anomalous failures-to-deliver 29.6 million shares (81.6% of outstanding shares) and peak trading volumes of 554 million shares on March 17, 2026, which was 15.3 times its outstanding shares. A federal judge ordered expedited discovery in May fiscal Q4 2026 to identify these defendants.
2. Expansion of AI-Powered Drug Discovery through Strategic Acquisitions and Partnerships.
Lunai Bioworks strengthened its AI-powered drug discovery pipeline through key strategic moves during this period. In March fiscal Q3 2026, the company completed a $20 million preferred issuance to acquire a Blood-Brain Barrier (BBB) Delivery Platform, intended for CNS Alzheimer's therapies and other neurotherapeutic applications. Furthermore, in April fiscal Q4 2026, Lunai Bioworks' subsidiary, BioSymetrics, signed a Letter of Intent with Geneial, Inc. to collaborate on building rare disease patient cohorts for pharmaceutical partnerships, particularly focusing on rare neurological disorders. This was followed by a foundation-funded collaboration with BrainStorm Therapeutics in May fiscal Q4 2026, targeting AI discovery for Parkinson's and rare epilepsy.
Show more
Updated on 6/22/2026
Lunai Bioworks (LNAI) stock has gained about 40% since 2/28/2026 because of the following key factors:
1. Regained Nasdaq Compliance Following Reverse Stock Split and Addressed Allegations of Naked Short Selling.
Lunai Bioworks' stock experienced significant upward movement after regaining compliance with Nasdaq's minimum bid price requirement. The company announced a 1-for-8 reverse stock split on May 20, 2026, to address its listing requirements. Subsequently, on June 11, 2026 (disclosed June 17, 2026), Nasdaq confirmed Lunai Bioworks had satisfied the $1.00 minimum bid price rule, leading to an 80.88% surge in share price to $5.15 in after-hours trading. Concurrently, the company pursued legal action against unidentified parties for alleged "naked" short-selling and manipulative trading, citing anomalous failures-to-deliver 29.6 million shares (81.6% of outstanding shares) and peak trading volumes of 554 million shares on March 17, 2026, which was 15.3 times its outstanding shares. A federal judge ordered expedited discovery in May fiscal Q4 2026 to identify these defendants.
2. Expansion of AI-Powered Drug Discovery through Strategic Acquisitions and Partnerships.
Lunai Bioworks strengthened its AI-powered drug discovery pipeline through key strategic moves during this period. In March fiscal Q3 2026, the company completed a $20 million preferred issuance to acquire a Blood-Brain Barrier (BBB) Delivery Platform, intended for CNS Alzheimer's therapies and other neurotherapeutic applications. Furthermore, in April fiscal Q4 2026, Lunai Bioworks' subsidiary, BioSymetrics, signed a Letter of Intent with Geneial, Inc. to collaborate on building rare disease patient cohorts for pharmaceutical partnerships, particularly focusing on rare neurological disorders. This was followed by a foundation-funded collaboration with BrainStorm Therapeutics in May fiscal Q4 2026, targeting AI discovery for Parkinson's and rare epilepsy.
3. Entry and Growth in the Biodefense Market with Government Collaborations.
The company demonstrated significant progress in the biodefense sector, marking a new revenue stream and strategic positioning. In March fiscal Q3 2026, Lunai Bioworks, through its BioSymetrics subsidiary, launched the Pathfinder Consortium. This national academic-industry alliance aims to accelerate the discovery and development of chemical countermeasures for emerging threats, targeting U.S. countermeasure programs valued between $400 million and $1.2 billion, with a projected 3-year antidote development model. By April fiscal Q4 2026, Lunai Bioworks secured its first revenue-generating defense collaboration, deploying its AI platform for chemical threat assessment. A CEO letter to shareholders in June fiscal Q4 2026 further highlighted the alignment of its Augusta platform with priorities outlined in the 2027 Defense Authorization Bill for AI-enabled biological screening against neurotoxic threat agents.
Show less
Lunai Bioworks (LNAI) stock has gained about 40% since 2/28/2026 because of the following key factors:
1. Regained Nasdaq Compliance Following Reverse Stock Split and Addressed Allegations of Naked Short Selling.
Lunai Bioworks' stock experienced significant upward movement after regaining compliance with Nasdaq's minimum bid price requirement. The company announced a 1-for-8 reverse stock split on May 20, 2026, to address its listing requirements. Subsequently, on June 11, 2026 (disclosed June 17, 2026), Nasdaq confirmed Lunai Bioworks had satisfied the $1.00 minimum bid price rule, leading to an 80.88% surge in share price to $5.15 in after-hours trading. Concurrently, the company pursued legal action against unidentified parties for alleged "naked" short-selling and manipulative trading, citing anomalous failures-to-deliver 29.6 million shares (81.6% of outstanding shares) and peak trading volumes of 554 million shares on March 17, 2026, which was 15.3 times its outstanding shares. A federal judge ordered expedited discovery in May fiscal Q4 2026 to identify these defendants.
2. Expansion of AI-Powered Drug Discovery through Strategic Acquisitions and Partnerships.
Lunai Bioworks strengthened its AI-powered drug discovery pipeline through key strategic moves during this period. In March fiscal Q3 2026, the company completed a $20 million preferred issuance to acquire a Blood-Brain Barrier (BBB) Delivery Platform, intended for CNS Alzheimer's therapies and other neurotherapeutic applications. Furthermore, in April fiscal Q4 2026, Lunai Bioworks' subsidiary, BioSymetrics, signed a Letter of Intent with Geneial, Inc. to collaborate on building rare disease patient cohorts for pharmaceutical partnerships, particularly focusing on rare neurological disorders. This was followed by a foundation-funded collaboration with BrainStorm Therapeutics in May fiscal Q4 2026, targeting AI discovery for Parkinson's and rare epilepsy.
3. Entry and Growth in the Biodefense Market with Government Collaborations.
The company demonstrated significant progress in the biodefense sector, marking a new revenue stream and strategic positioning. In March fiscal Q3 2026, Lunai Bioworks, through its BioSymetrics subsidiary, launched the Pathfinder Consortium. This national academic-industry alliance aims to accelerate the discovery and development of chemical countermeasures for emerging threats, targeting U.S. countermeasure programs valued between $400 million and $1.2 billion, with a projected 3-year antidote development model. By April fiscal Q4 2026, Lunai Bioworks secured its first revenue-generating defense collaboration, deploying its AI platform for chemical threat assessment. A CEO letter to shareholders in June fiscal Q4 2026 further highlighted the alignment of its Augusta platform with priorities outlined in the 2027 Defense Authorization Bill for AI-enabled biological screening against neurotoxic threat agents.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 40.0% change in LNAI stock from 2/28/2026 to 6/22/2026 was primarily driven by a 9.2233720368547763E17% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282026 | 6222026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.96 | 4.15 | 40.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 619.1 | |
| Shares Outstanding (Mil) | 3 | 3 | -6.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2026 to 6/22/2026| Return | Correlation | |
|---|---|---|
| LNAI | 40.0% | |
| Market (SPY) | 8.8% | 3.5% |
| Sector (XLV) | -5.9% | 0.2% |
Fundamental Drivers
The -56.0% change in LNAI stock from 11/30/2025 to 6/22/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 6222026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.44 | 4.15 | -56.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 619.1 | |
| Shares Outstanding (Mil) | 3 | 3 | -9.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 6/22/2026| Return | Correlation | |
|---|---|---|
| LNAI | -56.0% | |
| Market (SPY) | 9.5% | 5.7% |
| Sector (XLV) | -4.0% | -4.8% |
Fundamental Drivers
The 67.5% change in LNAI stock from 5/31/2025 to 6/22/2026 was primarily driven by a 9.2233720368547763E17% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 5312025 | 6222026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.48 | 4.15 | 67.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 619.1 | |
| Shares Outstanding (Mil) | 2 | 3 | -35.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2025 to 6/22/2026| Return | Correlation | |
|---|---|---|
| LNAI | 67.5% | |
| Market (SPY) | 27.7% | 3.5% |
| Sector (XLV) | 15.2% | 19.6% |
Fundamental Drivers
The -42.3% change in LNAI stock from 5/31/2023 to 6/22/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 5312023 | 6222026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.19 | 4.15 | -42.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 619.1 | |
| Shares Outstanding (Mil) | 1 | 3 | -77.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2023 to 6/22/2026| Return | Correlation | |
|---|---|---|
| LNAI | -42.3% | |
| Market (SPY) | 85.1% | 3.7% |
| Sector (XLV) | 23.4% | 12.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| LNAI Return | 147% | -86% | 208% | -74% | 6% | -46% | -84% |
| Peers Return | -37% | -56% | 23% | -29% | 74% | 14% | -53% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 100% |
Monthly Win Rates [3] | |||||||
| LNAI Win Rate | 58% | 42% | 50% | 50% | 25% | 50% | |
| Peers Win Rate | 33% | 35% | 52% | 35% | 60% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| LNAI Max Drawdown | -43% | -89% | -69% | -92% | -89% | -83% | |
| Peers Max Drawdown | -60% | -66% | -62% | -57% | -50% | -37% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TEM, RXRX, SDGR, GH, RLAY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/22/2026 (YTD)
How Low Can It Go
| Event | LNAI | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -66.5% | -18.8% |
| % Gain to Breakeven | 198.6% | 23.1% |
| Time to Breakeven | 120 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -66.0% | -7.8% |
| % Gain to Breakeven | 194.0% | 8.5% |
| Time to Breakeven | 126 days | 18 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -61.2% | -6.7% |
| % Gain to Breakeven | 157.5% | 7.1% |
| Time to Breakeven | 42 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -43.9% | -33.7% |
| % Gain to Breakeven | 78.4% | 50.9% |
| Time to Breakeven | 29 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -11.0% | -19.2% |
| % Gain to Breakeven | 12.4% | 23.8% |
| Time to Breakeven | 9 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -74.5% | -3.7% |
| % Gain to Breakeven | 292.9% | 3.9% |
| Time to Breakeven | 223 days | 6 days |
In The Past
Lunai Bioworks's stock fell -66.5% during the 2025 US Tariff Shock. Such a loss loss requires a 198.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | LNAI | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -66.5% | -18.8% |
| % Gain to Breakeven | 198.6% | 23.1% |
| Time to Breakeven | 120 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -66.0% | -7.8% |
| % Gain to Breakeven | 194.0% | 8.5% |
| Time to Breakeven | 126 days | 18 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -61.2% | -6.7% |
| % Gain to Breakeven | 157.5% | 7.1% |
| Time to Breakeven | 42 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -43.9% | -33.7% |
| % Gain to Breakeven | 78.4% | 50.9% |
| Time to Breakeven | 29 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -74.5% | -3.7% |
| % Gain to Breakeven | 292.9% | 3.9% |
| Time to Breakeven | 223 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -66.7% | -12.2% |
| % Gain to Breakeven | 200.0% | 13.9% |
| Time to Breakeven | 601 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -75.0% | -6.8% |
| % Gain to Breakeven | 300.0% | 7.3% |
| Time to Breakeven | 755 days | 15 days |
In The Past
Lunai Bioworks's stock fell -66.5% during the 2025 US Tariff Shock. Such a loss loss requires a 198.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Lunai Bioworks (LNAI)
Lunai Bioworks (LNAI), operating as Enochian Biosciences, Inc., is a pre-clinical stage biotechnology company focused on the research and development of innovative pharmaceutical and biological products for human treatment. The company’s core mission is to address significant unmet medical needs in areas such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and various types of cancer.
The company's pipeline features several promising candidates. Its lead programs include ENOB-HV-01, an autologous HIV curative treatment; ENOB-HV-11 and ENOB-HV-12, which are preventative and therapeutic HIV vaccines, respectively; and ENOB-HB-01, designed to target the hepatitis B virus polymerase. In the oncology space, Lunai Bioworks is developing ENOB-DC-11, an off-the-shelf dendritic cell vaccine for multiple solid tumors, and ENOB-DC-21, a non-specific vaccine intended for intratumoral injection.
Lunai Bioworks primarily targets the global market of patients suffering from these severe diseases, aiming to develop life-changing therapies. As a pre-clinical stage company, its progress is significantly bolstered by strategic collaborations with leading research institutions. It has established partnerships with prestigious organizations such as The Scripps Research Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute.
AI Analysis | Feedback
A very early-stage Gilead Sciences, but with a broader ambition across HIV, hepatitis, influenza, and cancer treatments and vaccines.
A pre-clinical Moderna or BioNTech, focused on developing new vaccines and therapies for diseases like HIV, hepatitis, and cancer.
AI Analysis | Feedback
- ENOB-HV-01: An autologous HIV curative treatment.
- ENOB-HV-11: A preventative vaccine targeting HIV.
- ENOB-HV-12: A therapeutic vaccine designed to treat HIV.
- ENOB-HB-01: A product coopting HBV polymerase for treating Hepatitis B virus.
- ENOB-DC-11: An off-the-shelf DC vaccine developed for multiple solid tumors.
- ENOB-DC-21: A non-specific vaccine for intratumoral injection against various cancers.
AI Analysis | Feedback
As a pre-clinical stage biotechnology company, Lunai Bioworks (LNAI) is primarily engaged in the research and development of pharmaceutical and biological product candidates. At this stage, the company does not have commercialized products on the market and therefore does not have major customers in the traditional sense, whether they be other companies or individual consumers purchasing its products.
AI Analysis | Feedback
null
AI Analysis | Feedback
David Weinstein, Chief Executive Officer
David Weinstein was appointed CEO of Lunai Bioworks in 2024. He has been instrumental in commercializing Lunai's AI platform for drug discovery, particularly for CNS diseases and cancer, and showcasing it on platforms like CNBC. Prior to his role at Lunai Bioworks, Mr. Weinstein was involved in Investment Banking at Dawson James Securities, Inc.
Nathen Fuentes, Chief Financial Officer
Nathen Fuentes assumed the role of Chief Financial Officer for Lunai Bioworks in January 2025. His previous experience includes serving as the Chief Financial Officer at Telomir Pharmaceuticals and Emergence Health Holdings, and as Controller of Glytec. He also has experience as an Experienced Associate at Price Waterhouse Coopers and in leading acquisition and organic growth initiatives.
Dr. Gabe Musso, Chief Scientific Officer, BioSymetrics
Dr. Gabe Musso serves as the Chief Scientific Officer of BioSymetrics, a segment of Lunai Bioworks focused on advanced computational biology and AI/machine learning. He is noted for his expertise in integrating molecular biology with clinical phenotyping to identify precision targets, particularly in the context of Parkinson's disease therapies.
AI Analysis | Feedback
```html
The key risks for Lunai Bioworks (symbol: LNAI) are primarily centered around its early-stage development, financial viability, and the highly competitive nature of the biotechnology industry.
- Funding and Going Concern Risk: As a pre-clinical stage biotechnology company, Lunai Bioworks lacks revenue-generating products and is heavily dependent on external financing to fund its extensive research and development activities. Recent reports indicate the company furloughed staff while seeking new financing in March 2026, and faced Nasdaq delisting actions in February 2026 due to its stock trading below the minimum bid price requirement. Furthermore, a February 2026 regulatory filing highlighted a "going concern and Nasdaq listing risk" for Lunai Bioworks, indicating substantial doubt about the company's ability to continue operations without additional funding.
- Clinical Trial Failure and Regulatory Approval Risk: Lunai Bioworks' entire pipeline of pharmaceutical and biological products, including candidates for HIV, HBV, influenza, coronavirus infections, and cancer, is in the pre-clinical stage of development. The drug development process is characterized by a high rate of failure in clinical trials and requires extensive time and significant capital investment. There is no guarantee that any of the company's product candidates will successfully complete clinical trials, demonstrate efficacy and safety, or receive the necessary regulatory approvals to be commercialized.
- Intense Competition: Lunai Bioworks operates in highly competitive therapeutic areas, including infectious diseases and oncology. These fields are dominated by numerous large pharmaceutical and biotechnology companies with significantly greater financial resources, established research and development capabilities, and marketing infrastructure. This intense competition poses a substantial risk to the company's ability to attract funding, secure top talent, differentiate its product candidates, and ultimately achieve market penetration if any products are successfully developed and approved.
AI Analysis | Feedback
null
AI Analysis | Feedback
The addressable markets for Lunai Bioworks' main products and services are detailed below:
Human Immunodeficiency Virus (HIV) Products
- Autologous HIV Curative Treatment (ENOB-HV-01): While a specific market for "HIV curative treatment" is not explicitly defined in current market reports, the broader global HIV treatment market is substantial. This market, which Lunai Bioworks' curative treatment would target, was valued at approximately USD 41.18 billion in 2025 and is projected to reach USD 56.34 billion by 2034. Another estimate places the global HIV drugs market at USD 40.21 billion in 2025, expected to reach USD 64.12 billion by 2035. The HIV market across the seven major markets (US, France, Germany, Italy, Spain, UK, Japan) is forecast to grow from USD 26.5 billion in 2023 to USD 32.1 billion in 2033, with the U.S. accounting for the majority of sales.
- Preventative HIV Vaccine (ENOB-HV-11) and Therapeutic HIV Vaccine (ENOB-HV-12): The global HIV vaccine market, encompassing both preventative and therapeutic approaches, is anticipated to expand significantly. It is projected to grow from USD 521.22 million in 2021 to USD 1.61 billion by 2033, at a compound annual growth rate (CAGR) of 9.833%. Another source estimates the HIV Vaccines Market to reach USD 1.18 billion by 2032, growing from USD 494.38 million in 2025. North America and Europe collectively command over 53% of the global market share in 2025.
Hepatitis B Virus (HBV) Product
- Coopting HBV Polymerase (ENOB-HB-01): The global hepatitis B therapeutics market was valued at USD 2.48 billion in 2025 and is projected to increase to USD 6.66 billion by 2034, with a CAGR of 12.09%. Another report indicates the Hepatitis B Treatment Market was valued at USD 4.899 billion in 2024 and is projected to reach USD 10.28 billion by 2035. North America held a significant market share, with the U.S. market alone projected to reach USD 1.36 billion by 2026. The chronic hepatitis B market across the seven major markets (U.S., EU4, U.K., Japan) was valued at approximately USD 1.6 billion in 2025.
Cancer Products
- Off-the-Shelf DC Vaccine for Multiple Solid Tumors (ENOB-DC-11) and Non-Specific Vaccine for Intratumoral Injection (ENOB-DC-21): These products fall under the dendritic cell cancer vaccine market and the broader solid tumor therapeutics market.
- Dendritic Cell Cancer Vaccine Market: The global dendritic cell cancer vaccine market was valued at USD 593.30 million in 2022 and is projected to grow to USD 3.2 billion by 2030, with a CAGR of over 20.7%. Another report estimates the global market at USD 2.01 billion in 2024, projected to reach USD 18.8 billion by 2035. North America is a leading region in this market.
- Solid Tumor Therapeutics Market: The global solid tumor therapeutics market was valued at USD 222.71 billion in 2023 and is expected to reach USD 885.44 billion by 2033, growing at a CAGR of 14.80%. North America accounted for 44% of the global market share in 2023. Another projection estimates the market to reach US$ 497.2 billion by 2033 from US$ 195.2 billion in 2023.
Infections Treatments
- Influenza Infections: The global influenza treatment market was valued at USD 5.91 billion in 2023 and is projected to reach USD 6.44 billion by 2030. The global influenza antiviral drugs market is projected to reach approximately USD 5.8 billion by 2033. North America holds the largest market share in the influenza drug market.
- Coronavirus Infections: The global COVID-19 therapeutics market size was valued at US$ 30.7 billion in 2021. It is projected to reach more than US$ 16.2 billion by the end of 2031. However, some reports indicate a contraction in this market, with projections showing a decline to USD 8.7 billion by 2033 from USD 32.54 billion in 2025, at a CAGR of -15.20%. North America held a major market share of over 40% in 2025.
AI Analysis | Feedback
Lunai Bioworks (LNAI), a pre-clinical stage biotechnology company leveraging AI for drug discovery and biodefense, is expected to drive future revenue growth over the next 2-3 years through several key initiatives. Given its pre-clinical stage, revenue generation is anticipated primarily from partnerships, licensing agreements, and grant funding, rather than direct product sales.
Here are 3-5 expected drivers of future revenue growth:
- Strategic Partnerships and Licensing for Central Nervous System (CNS) Programs: Lunai Bioworks aims to secure multiple partnerships and out-licensing agreements for its CNS programs, specifically targeting Parkinson's, Epilepsy, and Alzheimer's diseases. The company's January 2026 investor overview identifies securing six CNS partnerships as a key revenue catalyst for 2026. This strategy involves licensing therapeutic assets to pharmaceutical companies at preclinical or clinical stages.
- Oncology Program Partnerships and Out-licensing: The company is focused on securing oncology partnerships and out-licensing its immunotherapy programs. In November 2025, Lunai Bioworks secured its first Licensing Letter of Intent (LOI) following a breakthrough demonstrating complete tumor regression in humanized cancer models. Additionally, in February 2026, the company launched an AI oncology pilot with a clinical-stage partner to analyze Phase 2 metastatic colorectal cancer trial data, indicating active progress towards commercialization and partnership opportunities in oncology.
- Biodefense Initiatives and Government Contracts: Lunai Bioworks has highlighted biodefense as a significant area for revenue growth. Expected drivers include receiving government contracts for biodefense-related work, releasing findings on chemical weapon countermeasures, and forming industry and academic consortiums for biodefense. The company's launch of "Sentinel," an AI safeguard to block large language models from generating novel chemical weapons, in January 2026, further underscores its commitment and potential in this sector.
- Advancement of Alcohol Use Disorder (AUD) Program: In January 2026, Lunai Bioworks announced the expansion of its NIH-funded AI program into commercial Alcohol Use Disorder (AUD) drug discovery. This program is strategically positioned to generate revenue through partnerships, licensing deals, and non-dilutive funding opportunities as it advances differentiated therapeutic candidates toward clinical translation.
- Milestone Payments from Joint Ventures and Collaborations: The company has established a five-year partnership to form joint ventures (JVs), with each JV potentially receiving up to $40 million in funding from Deerfield. These arrangements are structured to provide milestone payments as drug candidates progress through development, representing a crucial non-dilutive revenue stream for Lunai Bioworks.
AI Analysis | Feedback
Share Issuance
- On June 20, 2023, Lunai Bioworks (Enochian Biosciences Inc.) entered into a purchase agreement with Lincoln Park Capital Fund, LLC to sell up to $20 million of its common stock over a 36-month term, and concurrently issued 696,021 shares as a commitment fee.
- For the nine months ended March 31, 2023, the company received $1,625,000 from the exercise of warrants and $2,483,000 from a private placement.
- On June 14, 2021, Enochian Biosciences Inc. made a deal to sell 3.87 million shares to investors.
Inbound Investments
- In June 2023, the company entered into a purchase agreement with Lincoln Park Capital Fund, LLC, allowing for the sale of up to $20 million of its common stock.
- As of January 2026, Lunai Bioworks (Enochian Biosciences Inc.) has a 5-year partnership with Deerfield to form joint ventures aimed at advancing new therapeutics, with Deerfield funding each joint venture with an initial pre-money valuation of $4 million and up to $40 million in total funding.
Outbound Investments
- As of January 1, 2026, Enochian Biosciences had not made any investments or acquisitions.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 16.26 |
| Mkt Cap | 2.4 |
| Rev LTM | 160 |
| Op Inc LTM | -283 |
| FCF LTM | -217 |
| FCF 3Y Avg | -248 |
| CFO LTM | -187 |
| CFO 3Y Avg | -228 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 39.0% |
| Rev Chg 3Y Avg | 31.0% |
| Rev Chg Q | -1.6% |
| QoQ Delta Rev Chg LTM | -0.4% |
| Op Inc Chg LTM | 18.1% |
| Op Inc Chg 3Y Avg | -1.2% |
| Op Mgn LTM | -477.5% |
| Op Mgn 3Y Avg | -87.3% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | -272.6% |
| CFO/Rev 3Y Avg | -40.8% |
| FCF/Rev LTM | -278.6% |
| FCF/Rev 3Y Avg | -44.3% |
Price Behavior
Price Behavior
| Market Price | $4.15 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 02/02/2015 | |
| Distance from 52W High | -65.4% | |
| 50 Days | 200 Days | |
| DMA Price | $2.63 | $5.26 |
| DMA Trend | up | down |
| Distance from DMA | 57.5% | -21.1% |
| 3M | 1YR | |
| Volatility | 188.9% | 943.9% |
| Downside Capture | -102.24 | 398.07 |
| Upside Capture | 24.08 | 343.69 |
| Correlation (SPY) | -5.3% | 3.8% |
LNAI Betas & Captures as of 5/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.70 | -1.82 | 0.84 | 1.26 | 2.77 | 1.37 |
| Up Beta | -11.45 | -6.52 | -10.55 | -5.60 | -12.12 | -1.82 |
| Down Beta | 15.09 | 7.85 | 2.11 | 2.28 | 1.40 | 1.95 |
| Up Capture | -8% | -23% | 505% | 127% | 1537% | 532% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 8 | 15 | 23 | 40 | 89 | 317 |
| Down Capture | -633% | 13% | 380% | 293% | 213% | 113% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 12 | 26 | 39 | 83 | 158 | 420 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LNAI | |
|---|---|---|---|---|
| LNAI | -85.2% | 224.9% | -0.06 | - |
| Sector ETF (XLV) | 14.7% | 15.0% | 0.70 | -0.7% |
| Equity (SPY) | 26.1% | 12.4% | 1.59 | 6.6% |
| Gold (GLD) | 24.1% | 27.5% | 0.77 | -1.5% |
| Commodities (DBC) | 18.5% | 18.8% | 0.77 | -4.8% |
| Real Estate (VNQ) | 11.8% | 13.8% | 0.57 | 0.3% |
| Bitcoin (BTCUSD) | -40.2% | 42.5% | -1.09 | 9.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LNAI | |
|---|---|---|---|---|
| LNAI | -62.4% | 154.8% | 0.02 | - |
| Sector ETF (XLV) | 5.5% | 14.7% | 0.19 | 6.8% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 12.7% |
| Gold (GLD) | 17.1% | 18.3% | 0.76 | -0.6% |
| Commodities (DBC) | 7.5% | 19.4% | 0.28 | -0.7% |
| Real Estate (VNQ) | 2.1% | 18.9% | 0.01 | 8.0% |
| Bitcoin (BTCUSD) | 9.4% | 54.1% | 0.37 | 6.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LNAI | |
|---|---|---|---|---|
| LNAI | -16.0% | 145.4% | 0.48 | - |
| Sector ETF (XLV) | 9.5% | 16.6% | 0.46 | 9.3% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 13.0% |
| Gold (GLD) | 12.2% | 16.1% | 0.62 | -0.3% |
| Commodities (DBC) | 6.0% | 18.0% | 0.26 | 0.3% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 10.1% |
| Bitcoin (BTCUSD) | 59.9% | 66.8% | 1.00 | 6.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 02/17/2026 | 10-Q |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 09/29/2025 | 10-K |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 02/19/2025 | 10-Q |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 10/10/2024 | 10-K |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 02/14/2024 | 10-Q |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 10/02/2023 | 10-K |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-Q |
| 09/30/2022 | 03/07/2023 | 10-Q |
| 06/30/2022 | 02/27/2023 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 02/17/2026 | 10-Q |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 09/29/2025 | 10-K |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 02/19/2025 | 10-Q |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 10/10/2024 | 10-K |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 02/14/2024 | 10-Q |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 10/02/2023 | 10-K |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-Q |
| 09/30/2022 | 03/07/2023 | 10-Q |
| 06/30/2022 | 02/27/2023 | 10-K |
| 03/31/2022 | 05/13/2022 | 10-Q |
| 12/31/2021 | 02/14/2022 | 10-Q |
| 09/30/2021 | 11/15/2021 | 10-Q |
| 06/30/2021 | 09/24/2021 | 10-K |
| 03/31/2021 | 05/17/2021 | 10-Q |
| 12/31/2020 | 02/16/2021 | 10-Q |
| 09/30/2020 | 11/12/2020 | 10-Q |
| 06/30/2020 | 09/23/2020 | 10-K |
| 03/31/2020 | 05/11/2020 | 10-Q |
| 12/31/2019 | 02/10/2020 | 10-Q |
| 09/30/2019 | 11/13/2019 | 10-Q |
| 06/30/2019 | 09/30/2019 | 10-K |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 6/22/2026